Uric acid is usually handed to patients as a single number. But the published data tie it to a bigger pattern of body chemistry and swelling. One study looked at 3,288 U.S. adults from NHANES 2007–2018. It used a combined uric acid–inflammation–metabolism (UIM) score. People in the top quarter of that score had 2.63 times the odds of osteoarthritis compared with the bottom quarter (adjusted OR 2.63, 95% CI 1.47–4.72).1
That is a link seen at one point in time. It is not proof that lowering uric acid prevents osteoarthritis. It is a reason to read the number in its setting. That is how we use it: as one input to a conservative-first plan, not a target on its own.
Key takeaways
- The published risk score treats uric acid as one of seven factors, not as a stand-alone marker.
- In NHANES data, high uric acid was linked to much higher odds of metabolic syndrome.
- Gout is common in adults of working age around the world. That is why the pattern shows up in clinic so often.
- All of this shows a link, not a cause. None of it proves that treating a lab value changes a joint outcome.
- At Regen.MD, metabolic work comes before structural work. See the Biological Baseline Program.
Why uric acid is read alongside metabolic markers
The seven variables in the UIM score
The UIM score was built with a statistics method called LASSO regression. It started from 14 possible factors and kept seven: uric acid, eGFR, serum creatinine, hs-CRP, waist size, HDL cholesterol, and BMI.1 Kidney function, inflammation, and body shape all sit inside the model. That is exactly the point.
In that study, the uric acid part added the most to the score, at 70.50%. Next came the metabolic part at 26.92% and the inflammation part at 2.58%.1 The combined score sorted people better than any single marker, with an AUC of 0.707.1
What the score does and does not show
The first group was 3,288 U.S. adults from NHANES 2007–2018. The score was then checked in 859 patients at a Chinese provincial hospital.1 Both are snapshot studies. The authors say the score sorts people by how likely they are to have osteoarthritis. It is not a cause. It is not a treatment target.
Is high uric acid linked to metabolic syndrome?
What NHANES 2013–2018 found
A separate NHANES study of 6,432 U.S. adults looked at high uric acid and metabolic syndrome. It was weighted to stand for about 94.7 million civilians living in the community. High uric acid meant above 7.0 mg/dL in men and 6.0 mg/dL in women. Before adjustment, people with high uric acid were 3.19 times more likely to have metabolic syndrome than those with normal levels.2
The link held up after adjustment. Two more models controlled for known metabolic syndrome risk factors. In them, people with high uric acid were 1.89 and 1.34 times more likely to have metabolic syndrome.2 The effect shrinks with adjustment. That is worth noticing, not glossing over.
How common is gout in working-age adults?
Around the world in 2021, there were about 6.08 million new gout cases and 32.7 million total cases among people aged 15 to 64. That comes from a Global Burden of Disease 2021 study released as a preprint.3 Men in that age group had about three times the rate of women.3
This is an estimate of how common gout is, not a finding about any one person. And it comes from a preprint that has not finished peer review. We include it because it explains why uric acid comes up so often in working-age patients. It tells us nothing about your knee.
How does Regen.MD approach uric acid and joint pain?
The Clinical Evaluation comes first
The first step is a physician-led Clinical Evaluation with Dr. Gurpreet Singh Padda, MD, MBA, MHP. It reviews your history, scans, and lab data, and ends in a written roadmap. The question is whether joint symptoms come from structure, from the metabolic terrain, or from both.
Metabolic optimization before structural work
The Biological Baseline Program checks fasting insulin, HbA1c, hs-CRP, a detailed lipid panel, and hormones. It adds coronary artery calcium scoring and blood vessel age scans. It is the required first phase for every joint and spine patient here. The metabolic bottleneck is fixed before any joint, spine, or nerve procedure is booked. Why we treat inflammation as terrain is explained in The Metabolic Bottleneck.
Where orthobiologics fit
Orthobiologics at Regen.MD include platelet-rich plasma into the joint and into tendons. They also include PRP into the bone under the cartilage, bone marrow aspirate concentrate, Lipogems, and orthobiologics into the disc. For advanced knee osteoarthritis, PRP is framed as a safe bridge therapy before joint replacement. None of these regrows cartilage, and we will not describe them that way. The full scope is laid out under orthobiologics.
When conservative care has truly run its course, surgery is on the table and discussed on its merits. Dr. Padda is a surgeon. Surgery is simply not the opening move.
For more information, get our free guide to knee pain and treatment options.
Have the lab pattern and the joint findings read together
Regen.MD begins with a physician-led Clinical Evaluation — a review of your history, imaging, and metabolic data, and a written terrain roadmap. Evaluation is contingent upon review of your data.
Questions? Call or text us.
Frequently Asked Questions
Is uric acid joint pain the same thing as gout?
Not necessarily. Gout is a crystal disease with its own pattern. A high uric acid level can also be part of a bigger body chemistry pattern, with no gout flare. Telling the two apart is a medical question, not a lab-value question. It is part of what the Clinical Evaluation is for.
What gets measured besides uric acid?
The NHANES study that built the uric acid-inflammation-metabolism score kept seven factors. They are uric acid, eGFR, serum creatinine, hs-CRP, waist size, HDL cholesterol, and BMI. That mix covers kidney function, inflammation, body shape and lipids. It is why uric acid is not read on its own. Our own panel is described in The Metabolic Audit.
Does lowering my uric acid prevent osteoarthritis?
That is not what the data show. The NHANES study is a snapshot. It shows a link between a combined score and how common osteoarthritis is at one point in time. It does not show a treatment effect. Anyone who tells you a lab number is a target with a promised joint result is going past the evidence. More of our writing on that gap is in the Regen.MD library.
Do I have to do the metabolic work before a joint procedure?
Yes. Metabolic optimization is the required first phase for every joint and spine patient at Regen.MD. The metabolic bottleneck is fixed before any joint, spine, or nerve procedure is booked. That order is the practice’s standing policy, not a case-by-case choice. We see patients at 4477 Woodson Rd, Suite 103, St. Louis, MO 63134, listed on our locations page.
Can too much uric acid cause joint pain?
It can be part of the picture in two ways. Gout is the familiar one: a crystal disease with its own pattern. Beyond gout, a high uric acid level is part of a bigger body chemistry pattern. In NHANES data, adults with the highest combined uric acid, inflammation and metabolism scores had 2.63 times the odds of osteoarthritis. That is a link, not a cause. So we read the number alongside your other markers.
Sources
- Lu C, Yang Z, Ji Y, Song Z, Wei L, Wang X. “Development and validation of a uric acid-inflammation-metabolism score for predicting osteoarthritis risk: evidence from NHANES 2007–2018 and an external Chinese cohort.” Frontiers in Endocrinology (Lausanne), 2026 Jun 18;17:1861185. https://pmc.ncbi.nlm.nih.gov/articles/PMC13322868/
- Bowden RG, Richardson KA, Richardson LT. “Uric acid and metabolic syndrome: findings from National Health and Nutrition Examination Survey.” Frontiers in Medicine (Lausanne), 2022 Dec 14;9:1039230. https://pmc.ncbi.nlm.nih.gov/articles/PMC9795410/
- Zhang JF, Cheng I-H, Cheng-Chung J, et al. “Global burden of gout in the working-age population (15–64 years), 1990–2021: a systematic analysis of the Global Burden of Disease Study 2021.” medRxiv preprint, posted January 30, 2026 (not peer reviewed). https://www.medrxiv.org/content/10.64898/2026.01.30.26345202v1